| Apr 2002 |
Acugen Neuropeutics Inc. was established in Seattle, Washington, USA, under the laws of State of Washington, to develop methods of treatment for degenerative eye diseases and pharmaceutical compound screening system |
| Mar 2003 |
Acugen Neuropeutics Inc. renamed as Acucela Inc. |
| Oct 2005 |
Initiated Visual Cycle Modulation (VCM) development |
| Mar 2006 |
Relocated Acucela headquarters to Bothell, Washington |
| Apr 2006 |
Initiated development for emixustat hydrochloride (emixustat), the lead VCM-based product candidate for the treatment of retinal diseases |
| Aug 2006 |
Opened Tokyo Office in Shinagawa Ward, Tokyo, Japan |
| May 2008 |
IND (investigational new drug) for emixustat for geographic atrophy secondary to dry age-related macular degeneration (GA secondary to dry AMD) was filed with the FDA (US Food and Drug Administration) |
| Jun 2008 |
Initiated Phase 1 clinical trial of emixustat for GA secondary to dry AMD |
| Sep 2008 |
Announced co-development and commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for emixustat |
| Mar 2010 |
Announced FDA Fast Track designation for emixustat for GA secondary to dry AMD |
| Sep 2010 |
Relocated Acucela headquarters to Seattle, Washington |
| Apr 2013 |
Initiated Phase 2/3b clinical trial of emixustat for GA secondary to dry AMD |
Sep 2013 |
Tokyo Office relocated to Shibuya Ward, Tokyo, Japan |
| Feb 2014 |
Acucela Initial Public Offering on Tokyo Stock Exchange Mothers Board |
| May 2015 |
Announced publication of pre-clinical data of emixustat for GA secondary to dry AMD |
| Jun 2015 |
Announced publication of results from Phase 2a clinical trial of emixustat for GA secondary to dry AMD |
| Dec 2015 |
Incorporated a subsidiary, Acucela Japan KK (eventual Kubota Pharmaceutical Holdings Co., Ltd.) in Japan |
| Mar 2016 |
Announced an exclusive option to license novel cataract treatment from UC San Diego and YouHealth Eyetech, Inc. |
| Apr 2016 |
Announced an exclusive license agreement for gene therapy from the University of Manchester, UK, for the treatment of retinal degenerative disease |
| May 2016 |
Initiated Phase 2 clinical trial with emixustat for proliferative diabetic retinopathy |
| May 2016 |
Announced top-line results from Phase 2b/3 clinical trial of emixustat for GA secondary to dry AMD |
| Jun 2016 |
Announced the termination of emixustat co-development and promotion agreement with Otsuka Pharmaceutical Co., Ltd. |
| Dec 2016 |
Completed the triangle merger and the redomicile transaction; Acucela Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. |
| Dec 2016 |
Kubota Pharmaceutical Holdings Co., Ltd. listed on the Tokyo Stock Exchange Mothers Board |
| Dec 2016 |
Announced R&D agreement to exclusively acquire novel retinal technology from University of Southern California and EyeMedics, LLC |
| Jan 2017 |
Announced FDA Orphan Drug Designation for emixustat for Stargardt disease |
| Jan 2017 |
Initiated Phase 2a clinical trial of emixustat for Stargardt disease |
| Feb 2017 |
Initiated development for home-based medical monitoring OCT device |
| Jun 2017 |
Tokyo Office relocated to Chiyoda Ward, Tokyo, Japan |
| Jan 2018 |
Announced a two-year development agreement with SIRION Biotech GmbH for gene delivery tools for ocular gene therapy |
| Jan 2018 |
Announced results from Phase 2 clinical trial of emixustat for proliferative diabetic retinopathy |
| Jan 2018 |
Announced results from Phase 2a clinical trial of emixustat for Stargardt disease |
| Mar 2018 |
Announced initiation of clinical trial for PBOS device |
| Nov 2018 |
Announced PBOS device clinical trial completion and results |
| Nov 2018 |
Initiated Phase 3 clinical trial of emixustat for Stargardt disease |
| Mar 2019 |
Signs Agreement to Develop a Compact OCT for NASA's Deep Space Missions |
| Jun 2019 |
Receives Orphan Designation from the European Medicines Agency (EMA) for Emixustat for the Treatment of Stargardt Disease |
| Apr 2020 |
Acucela Inc. launched its new corporate brand name and identity as Kubota Vision Inc. |
| Aug 2020 |
Received Orphan Products Clinical Trials Grants for Phase 3 Study of Emixustat in Stargardt Disease |
| Aug 2020 |
Completed Successful POC Clinical Study Using Wearable Myopia-Control Device Based on Kubota Glasses Technology |
| May 2021 |
Received Medical Device Registration Approval for Kubota Glass™ in Taiwan |
| Oct 2021 |
Received ISO 13485:2016 Certification |
| Apr 2022 |
Kubota Pharmaceutical Holdings Co., Ltd. listed on the Growth Market of the Tokyo Stock Exchange due to the Tokyo Stock Exchange market restructuring |
